We are excited to share that Fusix Biotech is the winner of the 2023 Merck Advance Biotech Grant. Fusix Biotech GmbH Biotech led by Dr. Jennifer Altomonte took home the first price, showcasing groundbreaking work that captivated everyone present. Read more on LinkedIn
We are excited to share that Fusix Biotech is one of winners of the 2023 Nucleate Venture Prize funded by BlueYard Capital. Read more on Blueyard.medium.com
In the Science4Life Venture Cup, Fusix Biotech from Munich convinced the jury. The start-up took third place with its idea of offering patients with difficult-to-treat cancers safe and effective immunotherapeutic therapy approaches with the help of a platform technology. Read more
We are excited to share that Fusix Biotech is one of winners of the Munich Business Plan competition organized by BayStartUP. Phase 1 is focused on the idea and competitive opportunity. Thanks to BayStartUP and all the jurors for the support. Read more
We are grateful for the chance to present at BioM's BioAngels event in front of venture capital investors, business angels and other private investors who invest in life sciences & health tech start-ups.
TUM Faszination Forschung: At the Klinikum rechts der Isar, researchers hope to harness the lethal power of viruses to combat malignant tumors. Jennifer Altomonte and her team are engi-neering viruses to optimize their therapeutic potential in cancer cells. Read more: PDF ducument
Oncolytic viruses (OVs) now claim a steadily growing market share in cancer therapeutics. These viruses offer an elegant and multimodal mode of action that enables a long-lasting systemic therapeutic success. m4 Award 2019 PD Dr. Jennifer Altomonte Teresa Krabbe Klinikum rechts der Isar, Technical University of Munich Commercialization of oncolytic viruses (FUSIX Biotech) Oncolytic [...]
Copyright:
Headquarters
München, Germany
Contact form
Imprint & Data Protection
